Nyheter fra ENA2020 konferansen ( 24-25 oktober )

BioBull
BGBIO 25.10.2020 kl 06:40 5307

BerGenBio deltar i helgen på ENA 2020’seminar.
Fikk noen med seg hva som er presentert ut over dette :

https://cm.eortc.org/cmPortal/Searchable/ENA2020/config/normal#!abstractdetails/0000897260

https://www.bergenbio.com/wp-content/uploads/2020/10/ENA_2020poster_Tilvestamab_BerGenBio.pdf


Apropos nye medisiner mot kreft - og COVID-19
Nobel pris vinner i fysiologi eller medisin fra 2019 Professor Sir Peter Ratcliffe sier i et foredrag:

https://event.eortc.org/ena2020/2020/10/24/1024/

Nobel Prize winner says scientific research has to be ‘passion-driven’


Scientists cannot be expected to drop everything they’re working on to turn their attention to beating COVID-19, according to the winner of the 2019 Nobel Prize in Physiology or Medicine, Professor Sir Peter Ratcliffe.

Speaking before he delivered the prestigious Michel Clavel lecture to the 32th EORTC-NCI-AACR [1] Symposium on Molecular Targets and Cancer Therapeutics, which was due to take place in Barcelona, Spain, and was moved online because of the coronavirus pandemic, Sir Peter said: “There is a belief in some quarters that the whole world of science should stop what it’s doing and work on coronavirus. I would argue that the best description of what we do is passion-driven research. The investigator has a passion for what they do, they have self-belief that they can solve a particular problem, and they have some belief that the problem is important, and that’s what drives us all on.”

He pointed out that much of the technology that has been turned to deal with COVID-19 emanated from cancer research, such as knowledge about how viruses infect cells, the immune response, how to engineer viral proteins to create potential vaccines, and some of the diagnostic tests for the coronavirus. However, researchers, like one of the world’s greatest footballers, need to work on what they feel passionate about.

“Messi would play football regardless of how much he is paid. That’s what you’re harnessing in science; it’s that human passion that some people have to push themselves and to find things out. If you have a problem like coronavirus and people say you have to work on coronavirus it doesn’t always harness that passion,” he said.

Spain is not only home to a great footballer, but also to many researchers who have paved the way for Sir Peter’s research on how cells sense and adapt to oxygen availability. Low levels of oxygen in cells, known as hypoxia, is an important component of many human diseases, including cancer, heart disease, stroke, vascular disease and anaemia. Hypoxia is common in solid tumours, and is associated with treatment resistance and poor prognosis.

Sir Peter said: “Spain has had a long history of hypoxia research, going back to Fernando De Castro in the 1920s who should have won the Nobel Prize but didn’t because his work was overlooked, partly because of the problems created by the Spanish Civil War. Spain has always been strong in this field.”

De Castro was the first person to describe cells specifically devoted to detecting changes in the chemical composition of blood as part of his research into the carotid body – a small structure that monitors changes in oxygen content in the blood and helps to control respiratory activity.

Together with Gregg Semenza and William Kaelin, Sir Peter won the 2019 Nobel prize for their discoveries about the molecular machinery that regulates the activities of genes in response to varying levels of oxygen.

In his lecture to the 32th EORTC-NCI-AACR Symposium, Sir Peter, who is professor of clinical medicine at the University of Oxford and clinical research director at the Francis Crick Institute in London, UK, will describe 30 years of research that led to his discoveries.

“There were two major aspects to the discovery that led to the Nobel. The first was the recognition that there are systems in the body’s cells for direct sensing of oxygen. It’s important because oxygen has to be delivered in precisely the right amounts to about 40 trillion cells in the human body and that’s not straightforward. Dysregulation, usually lack of oxygen, is a component of almost all human diseases including heart disease, circulatory diseases and cancer.

“The second part of the discovery was that we defined the mechanism by which that occurs and that was an unanticipated mechanism in cell signalling by which an oxygen-splitting enzyme, a dioxygenase, which is a biological catalyst, uses oxygen to mark the protein that directs gene expression; that protein is called hypoxia inducible factor, and that’s what Gregg Semenza discovered, and William Kaelin and I discovered the oxygen splitting mechanism.

“It’s important since enzymes are classically drug targets and, indeed, this enzyme is now a drug target, as is the HIF protein that it modifies and which directs gene expression. The work so far has entrained two sets of drug discovery programmes, both of which have led to drugs that are either in clinical practice or in clinical trials. One group of drugs aims to activate the system, to make the body think it’s hypoxic when it’s not and make corrective responses. Those corrective responses are currently being used to treat anaemia, particularly the anaemia that occurs in kidney disease where the patients lack a hormone called erythropoietin. They are also being used to treat other aspects of disease where low oxygen is a problem, such as in heart, lung or circulatory disease.

“The other class of drug is designed to antagonise the hypoxic response and those drugs are being used in cancer where it’s believed that hypoxia is actually driving the cancer development. When cancer grows rapidly, it often outgrows its oxygen supply and therefore it gets low oxygen inside the growing tumour. Low oxygen sets off this HIF system and aspects of the system have the ability to promote cancer. It’s possible by reducing the activity of the hypoxia inducible system to retard the growth of cancer and those drugs are looking pretty promising in the treatment of kidney cancer.

“These drug targets provide many potential uses and opportunities in medicine, but also difficulties in accurately defining what a drug will do in the body even when you know exactly what you’re targeting.”

(ends)

“Nobel Prize winner 2019: Elucidation of cellular oxygen sensing mechanisms: Implications for medicine”. Michel Clavel lecture by Professor Sir Peter Ratcliffe, Saturday 24 October, 16.45 – 17.30 hrs CEST, channel 1.

[1] EORTC [European Organisation for Research and Treatment of Cancer, NCI [National Cancer Institute], AACR [American Association for Cancer Research]. The Symposium takes place online on 24-25 October.

The European Organisation for Research and Treatment of Cancer (EORTC), the USA’s National Cancer Institute (NCI) and the American Association for Cancer Research (AACR) will join forces on 24-25 October 2020 to provide a “virtual” platform for presenting recent advances in pre-clinical and clinical research. Around 1,800 international experts in the field will be discussing innovations in drug development, ground-breaking new data, the selection of new targets for anti-cancer drugs, and the impact of new discoveries in molecular biology, in order to improve the survival and quality of life of cancer patients
Redigert 21.01.2021 kl 08:40 Du må logge inn for å svare
Slettet bruker
25.10.2020 kl 20:43 4859

Dette bør vel egentlig fyre BGBIO til godt over 30 i morgen?
Redigert 21.01.2021 kl 08:40 Du må logge inn for å svare
focuss
25.10.2020 kl 21:08 4758

Hvorfor det?
Redigert 21.01.2021 kl 08:40 Du må logge inn for å svare
Nanoq
26.10.2020 kl 09:02 4320

Interessant å se om markedet reagerer på ENA 2020’seminaret...

med mye markedsnegativitet og uro omkring Covid-19 og USA-valget, så skal man nok ikke være veldig optimistisk.
Redigert 21.01.2021 kl 08:40 Du må logge inn for å svare
MiniMe
26.10.2020 kl 09:14 4230

Jeg tror den reagerer på at den skal snart taes inn i WHO sitt Solidarity clinical trial for covid 19:) HA en fin dag.
Redigert 21.01.2021 kl 08:40 Du må logge inn for å svare
klaesp
26.10.2020 kl 09:19 4189

På tide å få noe som virker👍
Redigert 21.01.2021 kl 08:40 Du må logge inn for å svare
Docs
26.10.2020 kl 09:21 4170

Her lukter det shortskvis.
Redigert 21.01.2021 kl 08:40 Du må logge inn for å svare
Londonmannen
26.10.2020 kl 09:33 4064

Har utvilsom baller av ståd dem som sitter short i BgBio. Får håpe det er trykkfast stål de har den dagen det flagges at Bemcentinib er en av WHO sine utvalgte kandidater.
Redigert 21.01.2021 kl 08:40 Du må logge inn for å svare
Tradinator
26.10.2020 kl 09:41 3973

Bygger seg opp et minirally. 6,5% på en blytung børs. Ser ikke ille ut dette.
Redigert 21.01.2021 kl 08:40 Du må logge inn for å svare
Agurknytt
26.10.2020 kl 09:44 3924

Hvor høyt skal Bergenbio i dag da? Eller siger den ned igjen utover dagen? Bra volum, ser spennende ut :-)
Redigert 21.01.2021 kl 08:40 Du må logge inn for å svare
Hayen
26.10.2020 kl 09:45 3912

BGBIO: CARNEGIE STARTER DEKNING MED KJØPSANBEFALING, KURSMÅL 55
Oslo (TDN Direkt): Carnegie tar opp dekning av BerGenBio med en kjøpsanbefaling og kursmål 55 kroner pr aksje.
Redigert 21.01.2021 kl 08:40 Du må logge inn for å svare
Tradinator
26.10.2020 kl 09:46 3891

Good news:-)
Redigert 21.01.2021 kl 08:40 Du må logge inn for å svare
King
26.10.2020 kl 09:47 3877

Voleon Capital har så mye penger at et lite tap i BGBIO er sikkert innafor. Men de kan risikere å slite litt med å kjøpe tilbake 1% av aksjene dersom kursen virkelig tar av. Uten å være konspiratorisk sitter jeg ofte med følelsen om at noen vet mye mere enn andre. Om det gjelder shorterne her skal være uvisst.
Redigert 21.01.2021 kl 08:40 Du må logge inn for å svare
klaesp
26.10.2020 kl 10:19 3716

Ja, du kan spørre TM i første omgang 😀
Redigert 21.01.2021 kl 08:40 Du må logge inn for å svare
Nanoq
30.10.2020 kl 13:50 2698

Det var så ENA 2020 seminaret/konferansen...

Ellers er det jo mer på vei de neste 3 månedene:

Planlagte oppdateringer fra konferanser m.m. omkring BGBIO og Bemcentinib ( men forsinkelser kan jo skje p.g.a. Covid-19-situasjonen.) Mye spennende vil altså skje her de neste ca. 3 månedene.

Og så er COVID-19 programmet jo ikke nevnt her.

Nov 10-15: SITC – Society of Immunotherapy of Cancer : Bemcentinib + Keytruda

Dec 5-8: ASH – American Society of Heamatology: AML & MDS og Bemcentinib + LDAC, update

Jan 26-29, 2021 WCLC – World Congress of Lung Cancer : NSCLC, Bem + KEYTRUDA
Redigert 21.01.2021 kl 08:40 Du må logge inn for å svare
klaesp
30.10.2020 kl 14:35 2558

Takk for oppdatering 👍
Redigert 21.01.2021 kl 08:40 Du må logge inn for å svare
Slettet bruker
30.10.2020 kl 14:56 2498

Super oppdatering 💪🏻😊
Redigert 21.01.2021 kl 08:40 Du må logge inn for å svare
BioBull
30.10.2020 kl 23:07 2178

TM kjøper mer aksjer ... vet hva som skjer ....

BerGenBio ASA: Primary Insider notification

Bergen, Norway, 30 October 2020. Primary Insider Meteva AS has today purchased 38,547 shares in BerGenBio ASA at an average price of NOK 27.4822.

Following this transaction, Meteva AS holds 23,041,253 shares in BerGenBio ASA, corresponding to 26.41% of the shares in the company.
Redigert 21.01.2021 kl 08:40 Du må logge inn for å svare